Couñago F, Recio M, Del Cerro E, Cerezo L, Díaz Gavela A, Marcos F J, Murillo R, Rodriguez Luna J M, Thuissard I J, Martin J L R
Department of Radiation Oncology, Hospital Universitario Quirón Madrid, Calle Diego de Velázquez, 2, Pozuelo de Alarcón, 28223, Madrid, Spain,
Clin Transl Oncol. 2014 Nov;16(11):993-9. doi: 10.1007/s12094-014-1186-6. Epub 2014 May 28.
To evaluate the accuracy of preoperative 3T multiparametric magnetic resonance imaging (3TmMRI) for local staging of prostate cancer and its influence on the decision to change the clinical target volume (CTV), total dose and hormonal therapy when treating prostate cancer patients with radiotherapy.
From 2009 to 2013, 150 patients, who had confirmed prostate cancer and underwent a 3TmMRI before treatment with radical prostatectomy or radical radiation therapy, were included. Radiation therapy treatment (CTV, total dose and hormonal therapy) was initially determined on the basis of the clinical information, and radiation therapy plan was reevaluated after 3TmMRI review. The value of preoperative 3TmMRI in local staging and in the decision of radiotherapy treatment according to NCCN risk classification was analyzed.
3TmMRI performed correct, over- and under staging in 78.7 % (37/47), 6.3 % (3/47), 14.8 % patients (7/47), respectively. 3TmMRI identified 6 cT2a, 7 cT2b, 28 cT2c, 3 cT3a, 3 cT3b tumors. At final pathology, 5 tumors were classified as pT2a, 5 as pT2b, 30 as pT2c, 4 as pT3a, 3 as pT3b. After reviewing the MRI reports, the initial radiotherapy and hormonal therapy plan was changed in 33.9 % patients (35/103).
In our group of patients, 3TmMRI has been a reliable technique providing an optimal staging for prostate cancer. Its routine use could induce important changes in radiation therapy treatments in a significant number of such patients. However, more additional studies are needed to clarify this issue.
评估术前3T多参数磁共振成像(3TmMRI)用于前列腺癌局部分期的准确性,以及其对前列腺癌放疗患者临床靶区(CTV)、总剂量和激素治疗决策改变的影响。
纳入2009年至2013年期间150例确诊前列腺癌且在接受根治性前列腺切除术或根治性放射治疗前接受3TmMRI检查的患者。放射治疗方案(CTV、总剂量和激素治疗)最初根据临床信息确定,在3TmMRI检查后重新评估放射治疗计划。分析术前3TmMRI在局部分期以及根据美国国立综合癌症网络(NCCN)风险分类进行放疗治疗决策中的价值。
3TmMRI对患者分期正确、高估和低估的比例分别为78.7%(37/47)、6.3%(3/47)、14.8%(7/47)。3TmMRI识别出6例cT2a、7例cT2b、28例cT2c、3例cT3a、3例cT3b肿瘤。最终病理检查显示,5例肿瘤为pT2a,5例为pT2b,30例为pT2c,4例为pT3a,3例为pT3b。在查看MRI报告后,33.9%的患者(35/103)改变了最初的放疗和激素治疗方案。
在我们的患者群体中,3TmMRI是一种可靠的技术,可为前列腺癌提供最佳分期。其常规使用可能会使大量此类患者的放射治疗发生重要改变。然而,需要更多的研究来阐明这一问题。